source
- Frazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechsFrazier Life Sciences (FLS) has stacked up another sizable biotech-focused capital commitment, netting more than $1.1 billion for its long-running public fund.Fierce Biotech · 5h ago↗ source
- Novo Nordisk halts two IL-6 heart trials as Novartis suffers Phase 3 setbacks; Ionis wins first Alexander disease approvalNovo Nordisk announced it has ended two late‑stage studies of its investigational IL‑6 inhibitor ziltivekimab, which was being evaluated for cardiovascular disease. The decision follows an earlier…
- Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 fail